Literature DB >> 19200166

Expression of beta-defensin 4 is increased in human gastritis.

J-M Otte1, H M Neumann, S Brand, H Schrader, W E Schmidt, F Schmitz.   

Abstract

BACKGROUND: Infection with Helicobacter pylori (H. pylori) leads to the initiation of innate immune responses with increased antimicrobial peptide (AMP) expression in the gastric epithelium. This study aimed to determine the expression of the novel peptides beta-defensin 4 (hBD-4) and RNase 7 in infectious and non-infectious gastritis. Furthermore, pattern recognition receptors and mechanisms of regulation were characterized.
MATERIALS AND METHODS: Expression of AMPs was quantified by real-time PCR in biopsies obtained from healthy individuals and patients with infectious and non-infectious gastritis as well as in AGS gastric epithelial cells infected with H. pylori. Distribution of hBD-4 in the gastric mucosa was characterized by in-situ hybridisation and immunohistochemistry. The role of Toll-like receptors (TLRs) 2 and 4 and associated signalling pathways was addressed.
RESULTS: hBD-4 was expressed at low levels in gastric epithelial cells and was significantly upregulated in infectious and non-infectious gastritis. Standard eradication but not acid suppression therapy significantly decreased hBD-4 expression. Cytotoxin associated gene (cag)A positive H. pylori significantly increased the expression of hBD-4 whereas cagA negative organisms, non-viable bacteria or culture supernatants had no significant effect. Overexpression and downregulation of TLRs was not associated with an altered hBD-4 expression. However, blocking experiments revealed an essential role for the p38 mitogen-activated protein kinase. RNase7 was inconsistently expressed in biopsies and not significantly upregulated by H. pylori.
CONCLUSIONS: hBD-4 may play a significant role in H. pylori associated gastritis. Inconsistent expression of RNase 7 does not support a pivotal role for this peptide in response to infection with H. pylori.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200166     DOI: 10.1111/j.1365-2362.2008.02071.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  Antimicrobial peptide defensin: identification of novel isoforms and the characterization of their physiological roles and their significance in the pathogenesis of diseases.

Authors:  Yasuhiro Yamaguchi; Yasuyoshi Ouchi
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

2.  Effect of Helicobacter pylori eradication on TLR2 and TLR4 expression in patients with gastric lesions.

Authors:  Aline Cristina Targa Cadamuro; Ana Flávia Teixeira Rossi; Joice Matos Biselli-Périco; Patrícia Fucuta Pereira; Edla Polsinelli Bedin Mascarin Do Vale; Ricardo Acayaba; Kátia Ramos Moreira Leite; Eny Maria Goloni-Bertollo; Ana Elizabete Silva
Journal:  Mediators Inflamm       Date:  2015-03-22       Impact factor: 4.711

Review 3.  Antimicrobial Human β-Defensins in the Colon and Their Role in Infectious and Non-Infectious Diseases.

Authors:  Eduardo R Cobo; Kris Chadee
Journal:  Pathogens       Date:  2013-03-19

Review 4.  β-Defensins in the Fight against Helicobacter pylori.

Authors:  Raffaela Pero; Lorena Coretti; Ersilia Nigro; Francesca Lembo; Sonia Laneri; Barbara Lombardo; Aurora Daniele; Olga Scudiero
Journal:  Molecules       Date:  2017-03-07       Impact factor: 4.411

5.  Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity.

Authors:  Raffaela Pero; Tiziana Angrisano; Mariarita Brancaccio; Annarita Falanga; Lucia Lombardi; Francesco Natale; Sonia Laneri; Barbara Lombardo; Stefania Galdiero; Olga Scudiero
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 6.  A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins.

Authors:  Raffaela Pero; Mariarita Brancaccio; Sonia Laneri; Margherita-Gabriella De Biasi; Barbara Lombardo; Olga Scudiero
Journal:  Biomolecules       Date:  2019-06-18

Review 7.  The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics.

Authors:  Lorena Elena Meliț; Cristina Oana Mărginean; Maria Oana Săsăran
Journal:  Children (Basel)       Date:  2022-05-28

8.  Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance.

Authors:  Sabine Nuding; Michael Gersemann; Yoshio Hosaka; Sabrina Konietzny; Christian Schaefer; Julia Beisner; Bjoern O Schroeder; Maureen J Ostaff; Katunori Saigenji; German Ott; Martin Schaller; Eduard F Stange; Jan Wehkamp
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 9.  Differential inflammatory response to Helicobacter pylori infection: etiology and clinical outcomes.

Authors:  Jonathan Richard White; Jody Anne Winter; Karen Robinson
Journal:  J Inflamm Res       Date:  2015-08-13

10.  Helicobacter pylori downregulates expression of human β-defensin 1 in the gastric mucosa in a type IV secretion-dependent fashion.

Authors:  S R Patel; K Smith; D P Letley; K W Cook; A A Memon; R J M Ingram; E Staples; S Backert; A M Zaitoun; J C Atherton; K Robinson
Journal:  Cell Microbiol       Date:  2013-08-07       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.